Growth hormone gene deletion

On 22 June 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 377. The active ingredient is mecasermin rinfabate for treatment of patients with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.